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A B S T R A C T
The aim was to study the direct medical cost of epilepsy in children and adolescents and to determine the impact of ep-
ilepsy type and child’s age on total costs of treatment.
One-year prospective, prevalence based, »bottom up« analyses of sixty-nine (69) children with epilepsy (International
League Against Epilepsy criteria was used). Direct medical costs were calculated by summing annual costs of hospital
care, outpatient visits and antiepileptic drug (AED) treatment. The average annual cost per patient was 1293.0 . The
costs of hospital admissions were 942.9 € (72%), followed by drug treatment 240.0  (19%) and outpatient medical ser-
vices 121.2  (9%). The costs of epilepsy were significantly higher for children under 5 year of age. AED costs were statis-
tically significantly lower for children who received traditional AED (122.0) than modern AED (571.2). The costs of
epilepsy in children and adolescents in Croatia are congruent to those of developed countries. Costs significantly varied
regarding the child’s age. The cost of illness studies are an important first step towards the rational use of available re-
sources.
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Introduction
The overall medical progress and emerging new treat-
ments in the filed of epilepsy might greatly increase med-
ical cost of the disease, quite often without evident or
substantial benefit to the patients1,2. In countries with
limited health system resources reasonable and more
cautioned approach is essential.
There is a general opinion that better understanding
of economic aspect of epilepsy leads to the further devel-
opment of the medical care3. Studies on epilepsy costs are
scarce regarding children and adolescents population, no
matter of higher incidences of epilepsy4–7.
In Croatia there are only speculations about the ex-
penditures for chronic diseases as well as for epilepsy.
Treatment algorithms for most diseases are still develop-
ing as well as attention about the cost-benefit ratio or
cost-of-illness studies.
We calculated the direct medical costs of epilepsy in
children and adolescents to find out which health re-
source is mostly consumed as the first step towards the
rationalized use. Additionally, we wanted to study the
impact of the child’s age and epilepsy type on the total
cost of childhood epilepsy.
Patients and Methods
We performed prospective, prevalence based »bottom-
-up« analysis of direct medical costs of epilepsy in chil-
dren and adolescents. All patients were hospitalized at
the Department of Paediatrics and Department of Neu-
rology in University Hospital Centre Rijeka. The institu-
tion is tertiary medical centre, 1200-bed hospital, the sec-
ond large in Croatia. It provides medical care for 500 000
inhabitants of the Northern Adriatic region with its sur-
roundings. The patients were prospectively followed up
for one consecutive year from the establishing of diagno-
sis. Data were collected from hospital and outpatients ac-
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counting services during the two phases – April 2002-
April 2003, and September 2003-September 2004 to gain
better internal and external reproducibility. Statistically
significant differences between the two periods were not
found. Presented results were the average values for
these two periods.
Patients
The eligible patients were residents of the UCH Rijeka
catchments area. They were followed up for one year
upon the first diagnosis of epilepsy. Their epilepsy ful-
filled the standard ILAE diagnostic criteria8 or had clini-
cal and/or EEG evidence of a specific type of epilepsy. The
age of children varied from 3 months to 18 years. Neona-
tal convulsions were not included in the study.
Patients were grouped into categories regarding age:
5 years or under, from 6 to 10 years and from 11 to 18
years. Furthermore, regarding the epilepsy type popula-
tion was divided in to – general, partial (with or without
secondary generalization) or unclassified.
Cost calculations
Unit costs calculations were done following the Na-
tional Health Service-NHS (Croatian Institute for Health
Insurance) regulative. Cost calculations were summed
up for each medical or diagnostic procedure, as well as
for antiepileptic drugs (AED). The price of a medical pro-
cedure (hospital care, outpatient visits, laboratory tests,
diagnostic procedure, medical materials, etc) was defined
by NHS9,10. The price of consumed medical resources was
taken from the actual hospital invoice toward the NHS,
thus calculated costs represented factual expenses.
Direct medical expenditures related to epilepsy were
gained from the UHC Rijeka computer account data sys-
tem. The unit cost of resource was calculated using the
NHS tariffs indicated in Euros () by official exchange
rate at the study period.
Consumption of resources
Total costs were calculated by summing resources
consumed through one of three main costs categories
(hospital or outpatient or AED). In cooperation, total, av-
erage and per-patient-per-year values were calculated for
studied groups.
Hospital costs (inpatient medical care) included num-
ber of hospitalizations and days spent in hospital. It con-
sisted of costs for hospital care (including medical mate-
rials), laboratory costs, EEG cost, neuroimaging cost and
specialist consultations cost (by usual protocol at least
psychologist, ophthalmologist, ear-nose-throat specialist).
Outpatient medical care costs included specialists con-
sultations; paediatric neurologist, psychologist along with
medical resources consumed. Great parts of outpatients’
costs were diagnostics, mainly outpatient EEG and labo-
ratory tests as plasma AED levels. Primary care consul-
tation costs and costs attributable to epilepsy were not
calculated.
AED treatment costs were calculated through ac-
counting invoices. They were monitored by recording the
initial hospital treatment and treatment changes during
the study period to get total/cumulative quantities of ev-
ery AED in milligrams. Total costs were calculated by
multiplication of consumed quantities with price of daily
defined dosage (DDD) by the NHS price list for the fol-
lowed period10. The cost of AED treatment regarding
modern and traditional drug groups was presented sepa-
rately.
Lamotrigine, topiramate, vigabatrine and gabapentin
made the modern AED group. The majority of the tradi-
tional group AED were valproic acid and carbamazepine.
Statistical analysis
Descriptive statistics was used to analyse the sample
and specific patient subgroups. Student’s t-test and anal-
ysis of the variance or nonparametric (Kruskal-Wallis or
Mann-Whitney) tests, where appropriate, were used to
test the significance of differences among groups. The
children with unclassified epilepsy were excluded from
the statistical analysis due to a few patients in sample.
Results
During the investigation period 88 children and ado-
lescents were prospectively followed up for one year.
Nineteen (19) children were excluded from the study due
to residence outside UHC medical catchments or did not
fulfil the ILAE criteria. Finally, 69 children and adoles-
cents were included in the study. General characteristics
of the patients are presented in the Table 1.
There were more males than females. The group of
children aged 6–10 years included the most patients. Al-
most 60% of studied sample had partial epilepsy, with or
without secondary generalization. It was not possible to
determine the type of epilepsy for two children.
Preschool children were statistically significantly more
frequently hospitalized (1.72), stayed longer in hospital
(23.5 days) and had more outpatient consultations (5.39)
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TABLE 1





<= 5 years 18 24.6
6–10 years 33 49.3
11–18 years 18 26.1
Epilepsy syndrome
Partial epilepsy 41 59.4
1 Generalized epilepsy 26 37.7
Unclassified epilepsy 2 2.9
Total 69 100.0
than school children and adolescents, Table 2. There
were not found differences between school children and
adolescents through studied variables.
As seen in the table 2, the children and adolescents
with partial epilepsy were significantly more frequently
hospitalized (1.37) than those with generalized epilepsy.
There was no difference regarding the duration of hospi-
talization and the number of outpatient visits regarding
patients with generalized or partial epilepsy, Table 2.
Table 3 reports the mean annual cost per patient ob-
tained from 12-month follow up in general and stratified
to groups. The total annual cost per patient was 1 293.0
.
In all groups combined, the highest annual cost were
hospital admissions (942.99 ) followed by drug treat-
ment (240.06 ) and outpatient specialist consultations
(121.21 ). The main components of the total cost were
ranked as follows: hospital admissions, AED treatment
and outpatient visits respectively in all groups.
The preschool children had significantly the highest
total annual costs per patient (2 290.87 ), as well as hos-
pital costs (1 744.96 ) and outpatient medical interven-
tions (173.10 ). Preschool children with epilepsy also
had higher costs figures for drug treatment but not signi-
ficant in compare to the school-age children or adolescents.
The only significant difference regarding the school-age
children and adolescents was the cost of drug treatment.
Drug treatment costs in adolescents were significantly
higher than in school-aged children.
Considering epilepsy type, the highest cost was ob-
served in the group of children with unclassified epilepsy.
Due to a small number of patients with this entity, these
data can only be illustrative. The children with partial
epilepsy had higher total costs than the children with
generalized epilepsy. It was the same regarding the costs
per patient, hospital admissions, outpatient consulta-
tions and AED treatment, but it was not statistically sig-
nificant.
Drug-consumption patterns are shown in the table 4.
The most common prescription modality was monothe-
rapy with traditional AED (70%). They made 35.3% of
AED costs with the significantly lowest costs (122.03 )
of annual treatment. Twelve (12) patients (17%) with
monotherapy consisting of modern AED represented 41.3%
of AED costs, with the highest cost per-patient-per-year.
Nine patients (13%) with combined traditional and mod-
ern AED polytherapy represented 23.2% of AED costs.
The last mentioned group had substantial expenditures
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TABLE 2
HOSPITAL ADMISSIONS, DURATION OF STAY IN HOSPITAL AND SPECIALIST’S OUTPATIENTS VISITS BY STUDIED GROUPS
Age Hospital admissions Days in hospital Outpatient consultations
<= 5 years 1.72 a 23.56a 5.39 a
6–10 years 1.09 9.03 3.12
11–18 years 1.06 7.11 3.39
Epilepsy syndrome Hospital admissions Days in hospital Outpatient consultations
Partial epi. 1.37 b 13.39 3.90
Generalized epi. 1.04 9.81 3.73
Unclassified epi.c 1.50 23.00 2.00
General mean 1.25 12.32 3.78
Data expressed as mean per patient per year
a-p< 0.01, b-p<0,05, c-not included in statistical analyses
TABLE 3
ANNUAL COSTS PER PATIENT IN EUROS
Age Hospital costs Outpatients costs AED-s costs Total
<= 5 years 1 744.96 a 173.10a 391.03 2 290.87a
6–10 years 697.46 104.69 166.69 962.75
11–18 years 553.95 109.13 241.07b 889.49
Epilepsy syndrome Hospital costs Outpatients costs AED-s costs Total
Partial epi. 1 007.42 125.10 280.03 1 416.05
Generalized epi. 686.78 119.91 158.63 955.37
Unclassified epi.c 2 617.90 58.45 440.41 3 124.47
General mean 942.99 121.21 240.06 1 293.01
Values expressed as mean per patient per year
a-p< 0.01, b-p<0.05, c-not statistically calculated
of annual treatment and no significant difference in ex-
penditure between costs for modern monotherapy treat-
ment.
Distributions of costs by used resources are shown in
Figure 1. Hospital treatment was the highest consumer
of assets (72%), followed by AED treatment (19%). Out-
patient visits represent only 9% of costs of all used re-
sources.
Discussion
Our study was performed following the general rec-
ommendations regarding direct economic costs of epi-
lepsy11,12. Still, it can be compared with rather limited in-
vestigations due to scarce published reports regarding
childhood age4–7.
Guerrini et al. calculated the cost of childhood epi-
lepsy in Italy regarding health care setting5. In that
study the mean annual cost per epilepsy patient was 1
767  and the highest cost was in newly diagnosed cases
at the teaching hospital, 2 660 . The cost of epilepsy in
European countries varies from 900  to 3 000  per-pa-
tient-per- year for active cases13,14. The average cost per
patient in our study was 1 297 , similar to developed
countries. The overall regional or intra-regional develop-
ment create diverse economic circumstances, which might
cause difficulties in comparison or peer faced interpre-
tation5,6,7.
We found that in our settings hospitalizations were
both longer (average 12.3 days) and had more frequent
(average 1.25) comparing to western countries5,14,15. Ra-
ther predictably, hospital costs represented greater rela-
tive share (72%) of consumed resources. This result is in
line to the most of epilepsy costs studies, whether chil-
dren or adults populations16,17,13.
Differences among studies might be explained by the
discrepancies in terms of unit costs. The most important
proportion in majority of studies were hospital admission
costs, followed by drug consumption and outpatient ser-
vices13. In Croatia, i.e. in our study, unit costs are defined
by medical insurance provider9,10. Therefore it should be
considered when compared with cost-benefit, cost-effec-
tiveness or cost-minimalisation studies. Hospital costs in
studies varied and depended both on the organization
and financing of health care settings.
Our results clearly show that costs significantly vary
regarding the child’s age when epilepsy started. The
younger was the child, the costs were higher. Preschool
children ( 5 years) had statistically significantly higher
costs in all the studied parameters. The annual cost per
patient in children under 5 years was 2 290 , almost
double to general mean and 2.5 times more than in
school-aged children or adolescents. Similarly, costs were
also found higher in regard to AED consumption and
outpatients’ visits.
Cost variation in patients with epilepsy might be the
result of epilepsy type18. Guerrini at all showed that cost
of epilepsy varies significantly with severity of disease,
its temporal stage and its response to treatment5,19. In
our study we did not find any significant difference in
costs regarding partial and generalized epilepsies. We
presume that in our study the infants with West syn-
drome, who were more frequently hospitalized and had
longer hospitalization duration, increased the costs for
the entire generalized epilepsy group. The highest costs
were observed within unclassified epilepsy, but this re-
sult may be only illustrative due to a small number of pa-
tients.
Epilepsy is heterogeneous clinical condition, there-
fore the classification into partial, generalized and un-
classified type is relatively crude yardstick. A relatively
small number of cases in defined syndromes is an excep-
tion and reacts unpredictably. Additional challenge to
find more accurate economic burden of epilepsy is to cal-
culate the cost of epilepsy regarding the classification in
syndromes. It might modify the evidence that showed the
highest costs of drug resistant epilepsy.
Drug treatment made 19% of overall costs in our
study, figure 1. This finding should be explained with
caution. Most of published cost studies cannot be com-
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TABLE 4
ANTIEPILEPTIC DRUGS (AED) COSTS REGARDING TRADITIONAL AND MODERN ANTIEPILEPTICS AND THEIR PROPORTIONS
AED No. Patients Costs per patient per year /  % of AED cost
Traditional 48 (70%) 122.03 a 35.3%
Modern 12 (17%) 571.24 41.3%
Traditional + Modern 9 (13%) 427.97 23.2%
TOTAL 69 (100%) 240.06 100.0%







Fig. 1. Distributions of costs by used resources. AED- anti epilep-
tic drugs, Outp.Costs- outpatients costs.
pared due to different methodological approaches20. On
one hand, our result corresponds to many studies per-
formed in western countries, which showed that the sec-
ond source of direct costs of epilepsy are AED13. On the
other hand, we showed that the traditional AED repre-
sents a common prescription routine in Croatia, except
in children with modern AED, representing approxi-
mately 30% of all AED used21. Seventy percent (70%) of
our children were treated with traditional AED which
represented only 1/3 of total AED cost, table 4. Modern
AED may represent a significant burden in the direct
medical cost of epilepsy22,23,24. Four new generation AED
were approved and are available in Croatia: lamotrigine
(LTG) in 1995, viagabatrine (VGB) in 1997, topiramate
(TPM) in 1998 and gabapentine (GBP) in 2002. In our
study, 12 children treated with modern AED accounted
for 40,4% of the entire treatment cost. Our findings are
related to childhood and adolescence epilepsy treatment
and biase from the general population with epilepsy in
Croatia25. Moreover, the mean annual treatment cost per
patient in our study (240 ) was higher compared to the
results from Italy study (185 ) [5]. Such findings may re-
sult from the study at the university settings5,26.
To the best of our knowledge this is the first study re-
garding the costs of epilepsy in Croatia. Direct medical
cost of epilepsy in Croatian children and adolescents re-
garding the annual cost per person, costs of resource con-
sumed or cost distribution of AED are reasonably compa-
rable to those on the international level. In this manner
it would be difficult to make fair compare or appraise
concerning other chronic diseases in childhood due to
substantial differences in patophysiology, natural course
or temporal response to treatment. One must not disre-
gard both study settings and regional-external influences
when trying to draw conclusions from published litera-
ture.
Costs of epilepsy in our settings depended mostly on
the age when the disease appeared – the younger was the
child, the costs were higher. We did not in-calculate pri-
mary care costs, thus the annual costs might be even
higher.
Economic aspects of disease-treatment analysis must
insure benefits for patients, health care providers and
general health policy. In countries with new rising sys-
tems, limited resources assigned to the health care set-
tings demand rational allocation of the available funds.
Analyzing and reanalyzing the costs is the constant need
due to numerous options in diagnosis and treatment of
epilepsy. Cost-of-illness evaluation might be defined as a
creative process. All expenditure should be clearly de-
fined and pointed out for discussion.
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IZRAVNI MEDICINSKI TRO[KOVI DIJAGNOSTIKE I LIJE^ENJA EPILEPSIJE DJECE I
ADOLESCENATA
S A @ E T A K
Cilj istra`ivanja bio je utvrditi izravne medicinske tro{kove epilepsija u djece i adolescenata te utvrditi utjecaj tipa
epilepsije i dobi oboljelog djeteta na sveukupne tro{kove lije~enja. Provedena je jednogodi{nja prospektivna analiza
{ezdeset i devetero djece (69) oboljelih od epilepsije (po kriterijima Me|unarodne lige za brobu protiv epilepsije).Izravni
medicinski tro{kovi izra~unati su sumiranjem godi{njeg tro{ka hospitalizacije, ambulantnih obrada i primjene antiepi-
leptika. Srednja vrijednost godi{njeg tro{ka po pacijentu iznosila je 1293,0 . Tro{kovi hospitalizacije iznosili su 942,9 
(72%),tro{kovi terapije antiepilepticima 240,0  (19%), a tro{kovi ambulantne obrade 121,2  (9%). Sveukupni tro{kovi
zna~ajno su vi{i za djecu dobi ispod 5 godina. Tro{kovi lije~enja antiepilepticima zna~ajnije su ni`i u skupini djece
lije~ene tradicionalnim antiepilepticima (122,0) u usporedbi sa djecom lije~enom modernim antiepilepticima (571,2).
Tro{kovi lije~enja epilepsije u djece i adolescenata u Hrvatskoj sukladni su onima u razvijenim zemljama. Tro{kovi
zna~ajno variraju u ovisnosti o dobi djeteta. Evaluacija tro{kova lije~enja bolesti va`an su prvi korak prema racionalnoj
uporabi dostupnih resursa.
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